Abstract
Rare coding single nucleotide variants (SNV) and short insertions or deletions (indels) contribute to Alzheimer disease (AD) genetic risk, from pathogenic variants in autosomal dominant genes to risk factors with diverse effects. In contrast, copy number variants (CNV) have been scarcely studied, with the exception of a few autosomal dominant examples, such as APP gene duplications.
We took advantage from a large case-control dataset of 22,319 exomes (4,150 early-onset AD (EOAD, onset ≤65 years), 8,519 late onset AD (LOAD) and 9,650 controls) to detect CNVs. We first identified 17 causative CNVs in autosomal dominant genes (9 novel: 7 APP and 2 MAPT duplications). After exclusion of carriers of these, we performed an original two-step analysis: (i) a protein-coding genome-wide analysis at the transcript level using a gene dosage strategy (EOAD versus controls) and then (ii) an integrated loss-of-function (LOF) analysis gathering short truncating variants with CNV-deletions in genes prioritized in (i) and in a list of known AD risk genes.
We identified AD association with dosage of 20 genes at 4 different loci with a false discovery rate (FDR) below 10%, including the chr22q11.21 central region (FDR=0.0386), a region in linkage disequilibrium with the APOE locus on chr19 (FDR=0.0271), and two single-gene loci, namely FADS6 (FDR=0.0271), and ADI1 (FDR=0.0916). Replication in an independent dataset made of genotyping array data from 2,780 EOAD cases, 15,222 LOAD cases and 273,979 controls was consistent with the results obtained in the discovery dataset. The integrated LOF analysis helped narrowing the region of interest to the SCARF2-KLHL22-MED15 region at the 22q11.21 locus. In addition, the integrated LOF analysis highlighted rare deletions in the known AD-risk genes ABCA1 and ABCA7 that represented 10% (3/30) and 8.6% (10/115) of LOF alleles of these genes, respectively, as well as 4 TYROBP deletions. Finally, we identify CTSB LOF alleles as candidate rare AD risk factors (p=0.0089).
In conclusion, our results show that carriers of a deletion of FADS6 or a 22q11.21 deletion encompassing the SCARF2-KLHL22-MED15 region, including some patients with DiGeorge syndrome, may have a higher risk of developing AD. CNVs represent a source of genomic variation that can contribute to AD etiology in new genes but also in GWAS defined-genes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Catherine Schramm was supported by the Fondation pour la Recherche Medicale (ARF201909009263) and the Rouen metropole through the post-doctorants metropole funding. This research was conducted using the funding obtained by the following study cohorts: ADES-FR, AgeCoDe-UKBonn; Barcelona SPIN; AC-EMC; ERF and Rotterdam; ADC-Amsterdam; 100-plus study; EMIF-90+ Control Brain Consortium; PERADES; UCL-DRC EOAD; ADSP. Full consortium acknowledgements and funding sources are listed in the supplementary information document We thank the ADSP study for providing exome data from cases and controls (ADSP umbrella NG00067.v3). ADSP data were prepared, archived, and distributed by the National Institute on Aging Alzheimer Disease Data Storage Site (NIAGADS) at the University of Pennsylvania (U24AG041689), funded by the National Institute on Aging. The ADSP umbrella contains data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in the analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf. We thank the high-performance computing service at the University of Lille. S.L. was funded by ZonMw (PROMO-GENODE: a PROspective study of MOnoGEnic causes Of Dementia #733050512 and The YOD-INCLUDED project #10510032120002 and is part of the Dutch Dementia Research Programme) and received a substantial donation by Edwin Bouw Fonds, Dioraphte and Stichting TeamAlzheimer. S.L. further received funding for the GeneMINDS consortium, which is powered by Health∽Holland, Top Sector Life Sciences & Health. GeneMINDS receives co-financing from Brain Research Center, Prevail Therapeutics and Vigil Neurosciences. S.L. is recipiens of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health∽Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). More than 30 partners participate in ABOARD. ABOARD also receives funding from de Hersenstichting, Edwin Bouw Fonds and Gieskes-Strijbisfonds.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study, based on the retrospective analysis of existing data, was approved by the CERDE ethics committee from the Rouen University Hospital (CERNI/CERDE notifications 2017-015 and 2019-055).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
